Global Blood Therapeutics Stock Price Target and Analyst Ratings (NASDAQ:GBT)

Analyst Price Target for GBT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$93.82

▲ +115.69% Upside Potential

This price target is based on 17 analysts offering 12 month price targets for Global Blood Therapeutics in the last 3 months. The average price target is $93.82, with a high forecast of $152.00 and a low forecast of $45.00. The average price target represents a 115.69% upside from the last price of $43.50.

Buy

The current consensus among 17 investment analysts is to buy stock in Global Blood Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
8 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

9/4/2019

0 strong buy ratings
11 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

12/3/2019

0 strong buy ratings
10 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

3/2/2020

0 strong buy ratings
11 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

5/31/2020

0 strong buy ratings
14 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

8/29/2020

0 strong buy ratings
12 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

11/27/2020

0 strong buy ratings
12 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

1/26/2021

0 strong buy ratings
12 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

2/25/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
2/25/2021	William Blair	Downgrade	Outperform ➝ Market Perform		High	i
1/20/2021	Piper Sandler	Downgrade	Overweight ➝ Neutral	$75.00 ➝ $50.00	Low	i Rating by Joseph Catanzaro at Piper Sandler
12/16/2020	Morgan Stanley	Lower Price Target	Equal Weight	$67.00 ➝ $45.00	Low	i
12/15/2020	HC Wainwright	Reiterated Rating	Buy	$75.00	Low	i Rating by Debjit Chattopadhyay at HC Wainwright
12/8/2020	William Blair	Reiterated Rating	Buy		Medium	i
12/3/2020	Royal Bank of Canada	Initiated Coverage	Outperform	$75.00	High	i
11/18/2020	Cantor Fitzgerald	Lower Price Target	Overweight	$133.00 ➝ $120.00	Low	i Rating by A. Young at Cantor Fitzgerald
11/9/2020	Truist	Lower Price Target		$78.00 ➝ $55.00	Low	i
11/6/2020	Canaccord Genuity	Lower Price Target	Hold	$64.00 ➝ $45.00	High	i
11/6/2020	Morgan Stanley	Lower Price Target	Equal Weight	$68.00 ➝ $67.00	High	i
11/6/2020	Roth Capital	Lower Price Target	Buy	$131.00 ➝ $128.00	High	i Rating by E. Piros at Roth Capital
11/6/2020	Stifel Nicolaus	Lower Price Target	Buy	$120.00 ➝ $101.00	High	i
11/6/2020	Piper Sandler	Boost Price Target	Overweight	$75.00 ➝ $120.00	High	i Rating by Joseph Catanzaro at Piper Sandler
11/6/2020	Oppenheimer	Lower Price Target	Outperform	$102.00 ➝ $92.00	High	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
11/6/2020	Raymond James	Downgrade	Outperform ➝ Market Perform		High	i
10/13/2020	Morgan Stanley	Lower Price Target	Equal Weight	$75.00 ➝ $68.00	High	i
10/6/2020	Evercore ISI	Initiated Coverage	Outperform	$102.00	Medium	i
8/25/2020	Wedbush	Boost Price Target		$145.00 ➝ $152.00	Medium	i Rating by Liana Moussatos at Wedbush
8/24/2020	Raymond James	Initiated Coverage	Outperform	$115.00	Medium	i
8/6/2020	HC Wainwright	Reiterated Rating	Buy	$150.00	Low	i Rating by Debjit Chattopadhyay at HC Wainwright
8/6/2020	Stifel Nicolaus	Boost Price Target	Buy	$113.00 ➝ $118.00	High	i Rating by Benjamin Burnett at Stifel Nicolaus
7/29/2020	Piper Sandler	Reiterated Rating	Buy	$120.00	Low	i Rating by Joseph Catanzaro at Piper Sandler
7/20/2020	Roth Capital	Initiated Coverage	Buy	$129.00	Low	i Rating by E. Piros at Roth Capital
7/13/2020	Bank of America	Initiated Coverage	Buy	$92.00	High	i
7/1/2020	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$91.00 ➝ $103.00	High	i
6/25/2020	HC Wainwright	Reiterated Rating	Buy	$150.00	Low	i Rating by Debjit Chattopadhyay at HC Wainwright
6/25/2020	Canaccord Genuity	Reiterated Rating	Hold		Low	i
6/23/2020	Wedbush	Reiterated Rating	Buy	$145.00	High	i Rating by Liana Moussatos at Wedbush
6/15/2020	Oppenheimer	Reiterated Rating	Buy	$101.00	High	i
6/12/2020	Wells Fargo & Company	Reiterated Rating	Buy		High	i Rating by Jim Birchenough at Wells Fargo & Company
6/10/2020	Canaccord Genuity	Reiterated Rating	Hold		Low	i
5/12/2020	Wedbush	Reiterated Rating	Buy	$145.00	Low	i Rating by Liana Moussatos at Wedbush
5/7/2020	Cantor Fitzgerald	Boost Price Target		$105.00 ➝ $130.00	Low	i
5/7/2020	Nomura	Reiterated Rating	Buy	$112.00	Low	i
5/7/2020	Wells Fargo & Company	Boost Price Target	Overweight	$122.00 ➝ $133.00	Medium	i
5/7/2020	Oppenheimer	Boost Price Target	Outperform	$88.00 ➝ $101.00	Low	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
5/7/2020	Morgan Stanley	Boost Price Target	Equal Weight	$70.00 ➝ $75.00	High	i
4/27/2020	Stifel Nicolaus	Initiated Coverage	Buy	$112.00	Low	i
4/15/2020	Morgan Stanley	Lower Price Target	Equal Weight	$71.00 ➝ $70.00	Low	i
3/19/2020	Wedbush	Reiterated Rating	Buy	$145.00	Medium	i Rating by Liana Moussatos at Wedbush
3/18/2020	Oppenheimer	Lower Price Target		$100.00 ➝ $88.00	Low	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
3/18/2020	Canaccord Genuity	Reiterated Rating	Hold	$60.00	Medium	i
3/5/2020	Canaccord Genuity	Reiterated Rating	Hold	$60.00	Low	i
3/3/2020	Morgan Stanley	Lower Price Target	Equal Weight	$80.00 ➝ $71.00	High	i
1/31/2020	SunTrust Banks	Downgrade	Buy ➝ Hold	$110.00 ➝ $75.00	High	i
1/17/2020	Morgan Stanley	Boost Price Target	Equal Weight	$79.00 ➝ $80.00	Medium	i Rating by Matthew Harrison at Morgan Stanley
12/23/2019	Piper Jaffray Companies	Reiterated Rating	Buy	$120.00	N/A	i Rating by Danielle Brill at Piper Jaffray Companies
12/22/2019	Wedbush	Reiterated Rating	Buy	$143.00	Medium	i Rating by Liana Moussatos at Wedbush
12/18/2019	William Blair	Reiterated Rating	Buy		High	i Rating by Raju Prasad at William Blair
12/17/2019	JPMorgan Chase & Co.	Boost Price Target	Equal Weight	$58.00 ➝ $79.00	Low	i Rating by Cory Kasimov at JPMorgan Chase & Co.
12/10/2019	Piper Jaffray Companies	Boost Price Target		$95.00 ➝ $120.00	High	i
12/9/2019	Oppenheimer	Reiterated Rating	Buy	$100.00	Low	i
11/26/2019	Nomura Securities	Boost Price Target	Buy	$109.00 ➝ $112.00	High	i Rating by Christopher Marai at Nomura Securities
11/26/2019	Wedbush	Reiterated Rating	Buy	$143.00	High	i Rating by Liana Moussatos at Wedbush
11/26/2019	Janney Montgomery Scott	Boost Price Target	Buy	$75.00 ➝ $90.00	High	i
11/26/2019	SunTrust Banks	Boost Price Target	Buy	$110.00	High	i
11/26/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$80.00 ➝ $95.00	High	i
11/25/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$110.00 ➝ $98.00	High	i Rating by A. Young at Cantor Fitzgerald
11/6/2019	Canaccord Genuity	Initiated Coverage	Hold	$50.00	High	i
10/17/2019	Cantor Fitzgerald	Reiterated Rating	Overweight		High	i Rating by A. Young at Cantor Fitzgerald
10/14/2019	SunTrust Banks	Boost Price Target	Buy	$100.00	Low	i
10/9/2019	Cowen	Set Price Target	Buy	$83.00	Low	i Rating by Ritu Baral at Cowen Inc
10/9/2019	Wedbush	Reiterated Rating	Buy	$120.00	Low	i Rating by Liana Moussatos at Wedbush
10/9/2019	Wells Fargo & Company	Boost Price Target	Outperform	$96.00 ➝ $104.00	Medium	i
10/9/2019	HC Wainwright	Reiterated Rating	Buy	$150.00	Medium	i Rating by Debjit Chattopadhyay at HC Wainwright
10/8/2019	William Blair	Reiterated Rating	Buy		Low	i Rating by Raju Prasad at William Blair
9/12/2019	Wedbush	Reiterated Rating	Buy	$120.00	Medium	i Rating by Liana Moussatos at Wedbush
9/6/2019	HC Wainwright	Set Price Target	Buy	$150.00	Low	i Rating by Debjit Chattopadhyay at HC Wainwright
9/5/2019	Cowen	Set Price Target	Buy	$83.00	Low	i Rating by Ritu Baral at Cowen Inc
9/5/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low	i Rating by Cory Kasimov at JPMorgan Chase & Co.
9/5/2019	Wedbush	Boost Price Target	Outperform ➝ Hold	$103.00 ➝ $120.00	High	i Rating by Liana Moussatos at Wedbush
8/12/2019	Wedbush	Reiterated Rating	Outperform	$103.00	Low	i Rating by Liana Moussatos at Wedbush
8/11/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy	$75.00	Low	i
8/9/2019	Morgan Stanley	Set Price Target	Hold	$60.00	Medium	i Rating by Matthew Harrison at Morgan Stanley
8/8/2019	Cowen	Reiterated Rating	Buy	$83.00	Low	i
8/8/2019	HC Wainwright	Reiterated Rating	Buy	$150.00	Low	i Rating by Debjit Chattopadhyay at HC Wainwright
6/28/2019	Wedbush	Set Price Target	Buy	$103.00	Medium	i Rating by Liana Moussatos at Wedbush
6/25/2019	HC Wainwright	Reiterated Rating	Buy		Low	i Rating by Debjit Chattopadhyay at HC Wainwright
6/17/2019	Wedbush	Reiterated Rating	Buy	$107.00	Medium	i Rating by Liana Moussatos at Wedbush
6/16/2019	Cowen	Reiterated Rating	Buy		Medium	i
6/14/2019	Cantor Fitzgerald	Set Price Target	Buy	$96.00 ➝ $110.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
6/11/2019	Wedbush	Reiterated Rating	Buy	$107.00	Low	i
6/3/2019	Wedbush	Reiterated Rating	Buy	$95.00 ➝ $107.00	High	i
5/29/2019	The Goldman Sachs Group	Reiterated Rating	Neutral ➝ Neutral	$75.00	Low	i
5/13/2019	Wedbush	Reiterated Rating	Buy	$95.00	High	i Rating by Liana Moussatos at Wedbush
5/9/2019	Oppenheimer	Boost Price Target	Outperform	$82.00 ➝ $89.00	Medium	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
4/18/2019	Wedbush	Reiterated Rating	Outperform	$95.00	Medium	i Rating by Liana Moussatos at Wedbush
4/12/2019	HC Wainwright	Set Price Target	Buy	$150.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
4/1/2019	Wells Fargo & Company	Boost Price Target	Outperform ➝ Outperform	$85.00 ➝ $96.00	Low	i
3/5/2019	Wedbush	Boost Price Target	Outperform ➝ Outperform	$91.00 ➝ $95.00	Low	i Rating by Liana Moussatos at Wedbush
3/4/2019	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$55.00 ➝ $57.00	Low	i
2/28/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy	$75.00	Low	i
2/22/2019	Guggenheim	Initiated Coverage	Buy	$75.00	Low	i
1/30/2019	William Blair	Reiterated Rating	Buy		High	i Rating by Raju Prasad at William Blair
12/19/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$54.00 ➝ $55.00	High	i
12/4/2018	SunTrust Banks	Boost Price Target	Buy ➝ Positive	$90.00	Medium	i Rating by Yatin Suneja at SunTrust Banks, Inc.
12/4/2018	HC Wainwright	Set Price Target	Buy	$150.00	Medium	i Rating by Debjit Chattopadhyay at HC Wainwright
12/3/2018	William Blair	Reiterated Rating	Buy		High	i Rating by Raju Prasad at William Blair
12/3/2018	Cantor Fitzgerald	Set Price Target	Buy	$96.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
12/3/2018	Oppenheimer	Set Price Target	Buy	$82.00	High	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
11/28/2018	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$150.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
11/19/2018	Wedbush	Reiterated Rating	Buy	$73.00	Low	i Rating by Liana Moussatos at Wedbush
11/7/2018	Oppenheimer	Set Price Target	Buy	$74.00 ➝ $82.00	High	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
11/7/2018	William Blair	Reiterated Rating	Buy		High	i Rating by Raju Prasad at William Blair
11/5/2018	HC Wainwright	Set Price Target	Buy	$125.00	Low	i Rating by Debjit Chattopadhyay at HC Wainwright
11/1/2018	Oppenheimer	Set Price Target	Buy	$74.00	Medium	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
10/23/2018	Cantor Fitzgerald	Set Price Target	Buy	$96.00	Low	i Rating by Elemer Piros at Cantor Fitzgerald
10/19/2018	HC Wainwright	Set Price Target	Buy	$125.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
10/18/2018	William Blair	Reiterated Rating	Buy		High	i Rating by Raju Prasad at William Blair
10/17/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$96.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
10/2/2018	Cantor Fitzgerald	Set Price Target	Buy	$96.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
9/13/2018	HC Wainwright	Set Price Target	Buy	$125.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
8/23/2018	Cantor Fitzgerald	Set Price Target	Buy	$96.00	Medium	i Rating by Elemer Piros at Cantor Fitzgerald
8/23/2018	HC Wainwright	Set Price Target	Buy	$125.00	Low	i Rating by Debjit Chattopadhyay at HC Wainwright
8/13/2018	Cowen	Reiterated Rating	Buy	$83.00	High	i
8/8/2018	HC Wainwright	Set Price Target	Buy	$125.00	Low	i Rating by Debjit Chattopadhyay at HC Wainwright
8/8/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$96.00	Low	i Rating by Elemer Piros at Cantor Fitzgerald
8/6/2018	Wedbush	Reiterated Rating	Outperform ➝ Outperform	$73.00	Low	i Rating by L. Moussatos at Wedbush
8/6/2018	Piper Jaffray Companies	Initiated Coverage	Overweight	$80.00	Low	i
8/5/2018	SunTrust Banks	Set Price Target	Buy	$70.00	Low	i Rating by Yatin Suneja at SunTrust Banks, Inc.
8/5/2018	JPMorgan Chase & Co.	Reiterated Rating	Buy	$75.00	Low	i
8/2/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$96.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
7/27/2018	HC Wainwright	Reiterated Rating	Buy	$125.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
6/28/2018	Nomura Securities	Boost Price Target	Buy ➝ Buy	$91.00 ➝ $109.00	High	i
6/27/2018	HC Wainwright	Boost Price Target	Buy ➝ Buy	$73.00 ➝ $125.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
6/27/2018	Wells Fargo & Company	Boost Price Target	Outperform	$78.00 ➝ $85.00	High	i
6/27/2018	Cantor Fitzgerald	Boost Price Target	Overweight ➝ Overweight	$69.00 ➝ $96.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
6/18/2018	Wedbush	Reiterated Rating	Outperform	$70.00	Low	i Rating by L. Moussatos at Wedbush
5/24/2018	HC Wainwright	Set Price Target	Buy	$73.00	Low	i Rating by Debjit Chattopadhyay at HC Wainwright
5/21/2018	Wedbush	Reiterated Rating	Outperform	$70.00	High	i Rating by L. Moussatos at Wedbush
5/10/2018	HC Wainwright	Set Price Target	Buy	$73.00	Medium	i Rating by Debjit Chattopadhyay at HC Wainwright
5/9/2018	Cantor Fitzgerald	Set Price Target	Buy	$69.00	Medium	i Rating by Elemer Piros at Cantor Fitzgerald
5/8/2018	SunTrust Banks	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $77.00	High	i Rating by Yatin Suneja at SunTrust Banks, Inc.
5/8/2018	Oppenheimer	Lower Price Target	Outperform ➝ Outperform	$79.00 ➝ $74.00	High	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
4/26/2018	Needham & Company LLC	Reiterated Rating	Buy	$70.00	High	i
3/21/2018	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$61.00	High	i
3/14/2018	Wedbush	Reiterated Rating	Outperform	$73.00	Low	i
3/12/2018	HC Wainwright	Set Price Target	Buy	$73.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
3/6/2018	Morgan Stanley	Boost Price Target	Overweight ➝ Overweight	$58.00 ➝ $61.00	Low	i
3/1/2018	SunTrust Banks	Set Price Target	Positive ➝ Buy	$80.00	Medium	i
2/28/2018	William Blair	Reiterated Rating	Buy		High	i Rating by Raju Prasad at William Blair
2/28/2018	HC Wainwright	Set Price Target	Buy	$73.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
2/27/2018	Cantor Fitzgerald	Set Price Target	Overweight ➝ Overweight	$61.00 ➝ $72.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
2/13/2018	Janney Montgomery Scott	Initiated Coverage	Buy ➝ Buy	$75.00	Medium	i
1/23/2018	William Blair	Initiated Coverage	Outperform ➝ Outperform	$80.00	High	i Rating by R. Prasad at William Blair
1/11/2018	HC Wainwright	Set Price Target	Buy	$73.00	Medium	i Rating by Debjit Chattopadhyay at HC Wainwright
12/15/2017	Wedbush	Reiterated Rating	Outperform	$73.00	Low	i
12/14/2017	Needham & Company LLC	Boost Price Target	Buy ➝ Buy	$51.00 ➝ $70.00	Low	i
12/12/2017	Oppenheimer	Set Price Target	Buy	$53.00 ➝ $79.00	High	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
12/11/2017	Nomura Securities	Boost Price Target	Buy	$91.00	High	i
12/11/2017	HC Wainwright	Set Price Target	Buy	$73.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
12/11/2017	Cantor Fitzgerald	Set Price Target	Buy	$61.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
12/4/2017	Wedbush	Reiterated Rating	Outperform	$73.00	High	i
12/1/2017	HC Wainwright	Initiated Coverage	Buy	$73.00	High	i Rating by D. Chattopadhyay at HC Wainwright
11/13/2017	Oppenheimer	Set Price Target	Buy	$53.00	N/A	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
11/9/2017	Cowen	Reiterated Rating	Buy	$83.00	N/A	i
11/6/2017	SunTrust Banks	Boost Price Target	Buy	$67.00	N/A	i
10/30/2017	Oppenheimer	Set Price Target	Buy	$53.00	N/A	i
10/24/2017	Needham & Company LLC	Set Price Target	Buy	$51.00	N/A	i
10/23/2017	JPMorgan Chase & Co.	Reiterated Rating	Buy		N/A	i
10/23/2017	Oppenheimer	Set Price Target	Buy	$53.00	N/A	i
10/18/2017	Needham & Company LLC	Set Price Target	Buy	$51.00	N/A	i
10/11/2017	Oppenheimer	Set Price Target	Buy	$53.00	N/A	i
10/6/2017	Morgan Stanley	Reiterated Rating	Overweight	$51.00 ➝ $56.00	N/A	i
9/20/2017	Needham & Company LLC	Initiated Coverage	Buy ➝ Buy	$51.00	High	i
9/18/2017	Wedbush	Reiterated Rating	Ourperform	$73.00	Medium	i Rating by L. Moussatos at Wedbush
8/14/2017	Cowen	Reiterated Rating	Outperform	$83.00	Medium	i
8/8/2017	JPMorgan Chase & Co.	Reiterated Rating	Overweight ➝ Overweight	$44.00 ➝ $46.00	Medium	i
8/4/2017	Oppenheimer	Initiated Coverage	Outperform	$53.00	High	i
7/11/2017	Morgan Stanley	Reiterated Rating	Overweight		Low	i
5/2/2017	Wedbush	Reiterated Rating	Outperform	$73.00	High	i Rating by L. Moussatos at Wedbush
5/1/2017	Janney Montgomery Scott	Initiated Coverage	Buy	$37.00	Low	i
4/17/2017	SunTrust Banks	Initiated Coverage	Buy ➝ Buy	$56.00	High	i
3/20/2017	Roth Capital	Set Price Target	Buy	$47.00	Low	i Rating by M. Breidenbach at Roth Capital
3/20/2017	Wedbush	Reiterated Rating	Outperform ➝ Outperform	$73.00	Low	i Rating by L. Moussatos at Wedbush
3/15/2017	Cantor Fitzgerald	Initiated Coverage	Overweight ➝ Overweight	$61.00	Low	i
3/15/2017	JPMorgan Chase & Co.	Reiterated Rating	Buy	$44.00	Medium	i
3/1/2017	Nomura Instinet	Initiated Coverage	Buy ➝ Buy	$50.00	N/A	i
3/1/2017	Nomura Securities	Initiated Coverage	Buy		N/A	i
2/18/2017	Roth Capital	Set Price Target	Buy	$47.00	N/A	i Rating by M. Breidenbach at Roth Capital
1/10/2017	JPMorgan Chase & Co.	Reiterated Rating	Buy		N/A	i
1/4/2017	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$25.00	N/A	i
12/6/2016	Wedbush	Set Price Target	Buy	$73.00	N/A	i
12/5/2016	Cowen	Reiterated Rating	Buy		N/A	i
12/5/2016	Roth Capital	Set Price Target	Buy	$47.00	N/A	i Rating by M. Breidenbach at Roth Capital
11/28/2016	Roth Capital	Set Price Target	Buy	$47.00	N/A	i Rating by M. Breidenbach at Roth Capital
11/1/2016	Roth Capital	Initiated Coverage	Buy	$47.00	N/A	i Rating by M. Breidenbach at Roth Capital
10/26/2016	Cowen	Reiterated Rating	Outperform	$80.00 ➝ $83.00	N/A	i
10/25/2016	Wedbush	Boost Price Target	Outperform	$66.00 ➝ $73.00	N/A	i
9/30/2016	Wells Fargo & Company	Initiated Coverage	Outperform	$75.00 ➝ $23.05	N/A	i
8/22/2016	Wedbush	Reiterated Rating	Outperform	$66.00	N/A	i
8/14/2016	Morgan Stanley	Reiterated Rating	Buy	$62.00	N/A	i
8/10/2016	Wedbush	Reiterated Rating	Outperform	$66.00	N/A	i
6/10/2016	Morgan Stanley	Reiterated Rating	Buy		N/A	i
6/10/2016	Wedbush	Reiterated Rating	Outperform	$66.00	N/A	i
6/10/2016	Cowen	Reiterated Rating	Buy	$80.00	N/A	i
5/16/2016	Cowen	Reiterated Rating	Buy		N/A	i Rating by Ritu Baral at Cowen Inc
5/9/2016	Cowen	Reiterated Rating	Buy	$80.00	N/A	i Rating by Ritu Baral at Cowen Inc
4/17/2016	Cowen	Reiterated Rating	Buy		N/A	i Rating by Ritu Baral at Cowen Inc
3/31/2016	Cowen	Reiterated Rating	Outperform	$80.00	N/A	i
3/2/2016	Wedbush	Lower Price Target	Outperform	$94.00 ➝ $66.00	N/A	i Rating by Heather Behanna at Wedbush

(Data available from 2/25/2016 forward)

Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, Oxbryta (voxelotor) tablets, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating Oxbryta that has completed Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. The company has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.

Today's Range

Now: $43.50

$42.80

$46.82

50 Day Range

MA: $48.81

$45.25

$50.85

52 Week Range

Now: $43.50

$36.49

$83.69

Volume

3,894,997 shs

Average Volume

1,099,578 shs

Market Capitalization

$2.69 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.39

Frequently Asked Questions

What sell-side analysts currently cover shares of Global Blood Therapeutics?

The following sell-side analysts have issued reports on Global Blood Therapeutics in the last twelve months: Bank of America Co., Canaccord Genuity, Cantor Fitzgerald, Evercore ISI, HC Wainwright, Morgan Stanley, Nomura, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Roth Capital, Royal Bank of Canada, Stifel Nicolaus, The Goldman Sachs Group, Inc., Truist, Wedbush, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for GBT.

What is the current price target for Global Blood Therapeutics?

17 Wall Street analysts have set twelve-month price targets for Global Blood Therapeutics in the last year. Their average twelve-month price target is $93.82, suggesting a possible upside of 90.7%. Wedbush has the highest price target set, predicting GBT will reach $152.00 in the next twelve months. Canaccord Genuity has the lowest price target set, forecasting a price of $45.00 for Global Blood Therapeutics in the next year.
View the latest price targets for GBT.

What is the current consensus analyst rating for Global Blood Therapeutics?

Global Blood Therapeutics currently has 5 hold ratings and 12 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GBT will outperform the market and that investors should add to their positions of Global Blood Therapeutics.
View the latest ratings for GBT.

What other companies compete with Global Blood Therapeutics?

Other companies that are similar to Global Blood Therapeutics include Bausch Health Companies, Grifols, Mirati Therapeutics, Dr. Reddy's Laboratories, BridgeBio Pharma, Jazz Pharmaceuticals, Ultragenyx Pharmaceutical, Zai Lab, Arrowhead Pharmaceuticals, Ascendis Pharma A/S, Ionis Pharmaceuticals, ACADIA Pharmaceuticals, United Therapeutics, Schrödinger and GW Pharmaceuticals.

How do I contact Global Blood Therapeutics' investor relations team?

Global Blood Therapeutics' physical mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is 650-741-7700 and its investor relations email address is [email protected] The official website for Global Blood Therapeutics is www.gbt.com.

NASDAQ:GBT - Global Blood Therapeutics Stock Price Target and Predictions

Analyst Price Target for GBT

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Global Blood Therapeutics?

What is the current price target for Global Blood Therapeutics?

What is the current consensus analyst rating for Global Blood Therapeutics?

What other companies compete with Global Blood Therapeutics?

How do I contact Global Blood Therapeutics' investor relations team?